If you are deciding between tirzepatide and semaglutide, the question that matters most is rarely which one produces more weight loss. It is which one is more likely to keep you alive longer. The weight-loss question was settled in 2024 by SURMOUNT-5, the first Phase 3 head-to-head trial: tirzepatide wins. The cardiovascular question, until late 2025, was still mostly inferred from indirect comparison of separate placebo-controlled trials. Two new analyses changed that. This post walks through what they actually show.
In a real-world head-to-head comparison of tirzepatide versus semaglutide in patients with type 2 diabetes and elevated cardiovascular risk, published in Nature Medicine in November 2025, the hazard ratio for major adverse cardiovascular events was 1.06 (95 percent confidence interval 0.95 to 1.18).
That number requires careful reading. A hazard ratio of 1.0 would mean the two drugs are identical. A ratio above 1.0 means more events on tirzepatide; below 1.0 means more on semaglutide. The point estimate of 1.06 is slightly above 1.0, suggesting numerically more cardiovascular events on tirzepatide. But the confidence interval crosses 1.0, which means the difference is not statistically significant. The honest interpretation: in real-world cardiovascular outcomes, tirzepatide and semaglutide perform similarly. Tirzepatide is not superior. If anything, the data trends in the opposite direction.
This matters because most coverage of these drugs frames tirzepatide as unambiguously better. On weight loss, that framing is correct. On cardiovascular protection, it is not supported by the head-to-head data.
Semaglutide has the longer and stronger cardiovascular outcomes record.
SUSTAIN-6 (Marso et al., 2016, New England Journal of Medicine) randomized 3,297 patients with type 2 diabetes at high cardiovascular risk to semaglutide or placebo. Major adverse cardiovascular events occurred in 6.6 percent of the semaglutide group and 8.9 percent of placebo, hazard ratio 0.74 (95% CI 0.58 to 0.95). A 26 percent relative risk reduction, statistically significant for superiority over placebo.
SELECT (Lincoff et al., 2023, New England Journal of Medicine) randomized 17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes. Primary endpoint events occurred in 6.5 percent of the semaglutide group versus 8.0 percent on placebo, hazard ratio 0.80 (95% CI 0.72 to 0.90, P<0.001). A 20 percent relative reduction over a mean of 34 months. This is the largest GLP-1 cardiovascular outcome trial ever conducted in a nondiabetic population.
Tirzepatide's cardiovascular evidence is more recent and structured differently. SURPASS-CVOT (2025) compared tirzepatide head-to-head with dulaglutide, an older GLP-1 receptor agonist with established cardiovascular benefit. The trial established noninferiority, meaning tirzepatide produces cardiovascular benefit at least as good as dulaglutide. That is meaningful, but it is inherited benefit. Semaglutide proved cardiovascular benefit against placebo directly. Tirzepatide proved noninferiority against a drug that proved benefit against placebo.
The mechanistic answer is interesting. Tirzepatide is a dual agonist of the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). Semaglutide hits GLP-1 only. The addition of GIP receptor agonism is what drives tirzepatide's larger weight-loss advantage.
Pharmacologic GIP receptor activation in the obesity context appears to enhance lipid storage in subcutaneous fat depots (a beneficial pattern), reduce ectopic fat deposition in liver and muscle, and synergize with GLP-1 signaling in the brain to suppress appetite. These mechanisms explain the larger weight loss.
The cardiovascular question is different. GLP-1 receptor activation produces effects that plausibly drive cardiovascular benefit on its own: improved endothelial function, reduced inflammation in atherosclerotic plaques, modest blood pressure reduction, and direct effects on heart muscle under ischemic stress. These mechanisms are well characterized. GIP receptor activation, in contrast, has a less established cardiovascular profile. Some preclinical work suggests GIP signaling may be cardioprotective in its own right. Some suggests it may oppose certain GLP-1 cardiovascular effects.
The honest summary: GLP-1 agonism appears to be doing most of the cardiovascular work in both drugs. Adding GIP boosts weight loss but does not appear to add detectable cardiovascular benefit beyond what GLP-1 already provides. This is what the real-world head-to-head data is showing.
A post-hoc analysis of SURMOUNT-5 (Mamas et al., September 2025, European Heart Journal Open) modeled 10-year cardiovascular disease risk based on changes in cardiometabolic risk factors observed in SURMOUNT-5. The model projected approximately 70 fewer new cases of type 2 diabetes and 10 fewer cardiovascular events per 1,000 patients on tirzepatide compared with semaglutide at maximum tolerated doses.
This is the analysis most often cited to support tirzepatide cardiovascular superiority. Read with appropriate skepticism, it shows something narrower. First, these are modeled projections from a risk equation, not observed events from a trial. Risk equations assume that improvements in surrogate markers (weight, A1c, blood pressure, lipids) translate proportionally to hard endpoints. They often do not. Second, the Mamas analysis has six Eli Lilly co-authors. Lilly manufactures tirzepatide. This is industry-funded modeling work that favors the sponsor's product. It is not invalid, but it requires the disclosure most peptide and weight-loss media omits.
When industry-funded modeling work and academic real-world outcomes point in different directions, the academic data should carry more weight. The Krueger et al. Nature Medicine study (hazard ratio 1.06) is the real-world data. The Mamas et al. analysis is the model.
Three reasonable decision frames, depending on what you are optimizing for.
If your primary goal is maximum weight loss and you do not have established cardiovascular disease, tirzepatide is the better choice. SURMOUNT-1 produced approximately 22.5 percent weight loss at 72 weeks at the 15 mg dose. SURMOUNT-5 confirmed the advantage over semaglutide at maximum tolerated doses. The cardiovascular evidence is good enough; if there is no specific reason to prioritize semaglutide, take the larger weight loss.
If your primary goal is cardiovascular event prevention and you already have established cardiovascular disease, semaglutide has the better evidence base. SELECT is the largest and most directly relevant trial. SUSTAIN-6 added a placebo comparison in the diabetic population. The cardiovascular data on tirzepatide is real but inherited through noninferiority against another GLP-1, not established against placebo.
If your primary goal is glycemic control in type 2 diabetes, tirzepatide produced larger A1C reductions than semaglutide in SURPASS-2. Both drugs are effective; tirzepatide is more effective.
In all three cases, the choice is closer than the marketing suggests. A patient who tolerates tirzepatide at 15 mg for two years will likely do better than one who is escalated to semaglutide at 2.4 mg but discontinues. Tolerability and adherence at the highest sustainable dose matter more than the choice between the two compounds.
Retatrutide adds glucagon receptor agonism to GLP-1 and GIP. TRIUMPH-1 (May 2026) showed it produces larger weight loss than anything else in the class, with 28.3 percent at 80 weeks and up to 30.3 percent at 104 weeks at the highest dose. The cardiovascular question for retatrutide is genuinely open.
If the tirzepatide-versus-semaglutide pattern holds, retatrutide's weight-loss advantage may not translate into cardiovascular superiority. Glucagon receptor agonism has effects on hepatic glucose output, lean mass preservation, and energy expenditure that have their own cardiovascular profile, positive or negative. TRIUMPH-3, the ongoing cardiovascular outcomes trial in adults with established cardiovascular disease, will provide the answer. Until then, treating retatrutide as obviously cardioprotective because its weight loss is bigger would be the same mistake early tirzepatide enthusiasts made.
Tirzepatide produces more weight loss than semaglutide. The real-world cardiovascular outcomes data shows the two perform similarly on hard endpoints, with the point estimate trending slightly in semaglutide's favor. Semaglutide has the longer and stronger cardiovascular evidence base, with SELECT and SUSTAIN-6 both showing direct placebo-controlled benefit. Tirzepatide's cardiovascular benefit is inherited through noninferiority against dulaglutide.
If you read someone claiming tirzepatide is unambiguously cardioprotectively superior to semaglutide, they have either not read the head-to-head data, or they are working from the industry-funded model rather than the academic real-world study. The honest answer is that on cardiovascular outcomes, the two drugs are roughly tied.
Krueger et al. (2025). Nature Medicine. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.
Lincoff et al. (2023). New England Journal of Medicine. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial).
Marso et al. (2016). New England Journal of Medicine. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6 trial).
Mamas et al. (2025). European Heart Journal Open. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial.
Jastreboff et al. (2026). Eli Lilly press release. TRIUMPH-1 Phase 3 results for retatrutide.
Every Tuesday: one landmark study, one protocol, one regulatory update. Plus new research posts as they publish. Free.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use